Volume 5, Issue 2 pp. 90-95
Full Access

Ethical and practical problems of early anti-cancer drug trials: a review of the literature

KAREN COX BSc (Hons), RGN, Oncology Cert, DipHE, DN

Corresponding Author

KAREN COX BSc (Hons), RGN, Oncology Cert, DipHE, DN

Research Associate

Department of Nursing and Midwifery Studies, Faculty of Medicine and Health Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK

*Corresponding author.Search for more papers by this author
Mark Avis BA (Hons), MSc, RGN, RMN, RNT, Cert Ed

Mark Avis BA (Hons), MSc, RGN, RMN, RNT, Cert Ed

Lecturer

Department of Nursing and Midwifery Studies, Faculty of Medicine and Health Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK

Search for more papers by this author
First published: June 1996
Citations: 23

Abstract

Early clinical trials for new anti-cancer drug treatments typically use patients with cancer as research subjects. This paper identifies some of the ethical and practical concerns that arise from the recruitment of a vulnerable group of patients and their exposure to a drug of unknown risk or benefit. This review discusses the ethical principles related to recruitment and informed consent in cancer trials, and indicates that there is a lack of consensus concerning the requirements, process and practice of informed consent. It is suggested that, as yet, little is know about patients' decision making framework in this situation, and the need for further work that concentrates on the patient's point of view is highlighted. The paper concludes by discussing some of the difficulties associated with obtaining patients’opinions, and suggests that the use of a qualitative approach may overcome some of these problems.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.